Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023)
Ironwood Pharmaceuticals (IRWD) posted Income from Non-Controlling Interests of -$658000.0 for Q4 2023, up 52.01% sequentially from -$1.4 million in Q3 2023.
Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends
Ironwood Pharmaceuticals has reported Income from Non-Controlling Interests for 2 years, with the latest figure at -$658000.0 in Q4 2023.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$658000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$29.3 million (changed N/A YoY) and the FY2023 annual result came in at -$29.3 million, changed N/A from the prior year.
- Income from Non-Controlling Interests climbed to -$658000.0 in Q4 2023 per IRWD's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$658000.0 in Q4 2023 and troughed at -$27.3 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Ironwood Pharmaceuticals | 688.03 Mn | 608.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -658,000.00 |
| Sep 30, 2023 | -1.37 Mn |
| Jun 30, 2023 | -27.29 Mn |
| Sep 30, 2010 | 1.52 Mn |
| Jun 30, 2010 | -73,000.00 |